Investigational drug · Phase 3
Zasocitinib
Also called: TAK- 279, NDI-034858
Not approved by FDA. In 17 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
17
13 still active
All registered trials
14
Any phase or sponsor naming "Zasocitinib"
First trial start
2023
Nov 6, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
- Takeda17
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zasocitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Plaque Psoriasis
- Psoriatic Arthritis
- Crohn's Disease
- Ulcerative Colitis
- Nonsegmental Vitiligo
- Palmoplantar Psoriasis
- Hidradenitis Suppurativa
- Generalized Pustular Psoriasis
- Erythrodermic Psoriasis
Approved drugs for the same conditions: Plaque psoriasis · Psoriatic arthritis · Crohn's disease · Ulcerative colitis · Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Zasocitinib" as an intervention, largest first.
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesPivotal-lookingActive, not recruiting
TakedaTakeda (TAK)
NCT06671483 · 1,583 participants · Start Mar 3, 2025 · Primary completion May 18, 2027
Drug: Zasocitinib; Active Comparator and 1 more · For: Psoriatic Arthritis
Sites: Chandler, Arizona; Phoenix, Arizona; Fountain Valley, California · 184 sites in all
- Continuation Study of Zasocitinib in Adults With Psoriatic ArthritisPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07286058 · 1,182 participants (planned) · Start Mar 11, 2026 · Primary completion Dec 18, 2029
Drug: Zasocitinib · For: Psoriatic Arthritis
Sites: Tucson, Arizona; Fountain Valley, California; La Mesa, California · 111 sites in all
- A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)Pivotal-lookingNot yet recruiting
TakedaTakeda (TAK)
NCT07871721 · 644 participants (planned) · Start Jan 11, 2027 · Primary completion Apr 18, 2030
Drug: Zasocitinib · For: Psoriatic Arthritis
- A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque PsoriasisPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT06973291 · 606 participants · Start Jul 9, 2025 · Primary completion Apr 22, 2026
Drug: Zasocitinib; Deucravacitinib and 2 more · For: Plaque Psoriasis
Sites: Fort Smith, Arkansas; Hot Springs, Arkansas; Beverly Hills, California · 113 sites in all
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesPivotal-lookingActive, not recruiting
TakedaTakeda (TAK)
NCT06671496 · 601 participants · Start Mar 10, 2025 · Primary completion May 18, 2027
Drug: Zasocitinib; Placebo · For: Psoriatic Arthritis
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 120 sites in all
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06233461 · 268 participants (planned) · Start Mar 5, 2024 · Primary completion Feb 17, 2027
Drug: TAK-279; Placebo · For: Crohn's Disease
Sites: Murrieta, California; Orange, California; Clearwater, Florida · 201 sites in all
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
TakedaTakeda (TAK)
NCT06254950 · 213 participants · Start Mar 29, 2024 · Primary completion Jul 14, 2026
Drug: TAK-279; Placebo · For: Ulcerative Colitis
Sites: Los Angeles, California; Murrieta, California; Clearwater, Florida · 141 sites in all
- A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque PsoriasisPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07250802 · 210 participants (planned) · Start Dec 4, 2025 · Primary completion Jul 3, 2034
Drug: Zasocitinib; Placebo and 1 more · For: Plaque Psoriasis
Sites: Chula Vista, California; Fountain Valley, California; Hialeah, Florida · 38 sites in all
- A Study of Zasocitinib in Adults With Nonsegmental VitiligoPivotal-lookingActive, not recruiting
TakedaTakeda (TAK)
NCT07108283 · 207 participants · Start Nov 3, 2025 · Primary completion Mar 26, 2027
Drug: Zasocitinib · For: Nonsegmental Vitiligo
Sites: Bryant, Arkansas; Fountain Valley, California; Fremont, California · 67 sites in all
- A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)Recruiting
TakedaTakeda (TAK)
NCT06764615 · 192 participants (planned) · Start May 28, 2025 · Primary completion Dec 30, 2029
Drug: Zasocitinib · For: Crohn's Disease; Ulcerative Colitis
Sites: Glen Burnie, Maryland; Tyler, Texas; Chongqing, China · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Selective Tyrosine Kinase 2 Targeting for the Management of Immune-mediated Inflammatory Skin Diseases: A New Paradigm.
De Luca DA, Koumprentziotis IA, Thaçi D · Am J Clin Dermatol 2026
- Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients.
Krebs M, Gulyás L, Fazekas KK, et al. · J Eur Acad Dermatol Venereol 2026
- Corrigendum to "Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective and Potent Allosteric TYK2 Inhibitor" Journal of Investigative Dermatology, Volume 146, Issue 1, January 2026, Pages 214-222.e7.
Mehrotra S, Sano Y, Halkowycz P, et al. · J Invest Dermatol 2026
- Impact of Selective Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) on Molecular Pathways and Correlated Clinical Response in Patients With Active Psoriatic Arthritis.
Choudhury A, Cheng J, Tang J, et al. · ACR Open Rheumatol 2026
- Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety.
Hagino T, Kanda N · J Dermatol 2026
- Evaluating zasocitinib as an oral therapy for moderate to severe plaque psoriasis.
McGuirt V, Razler D, Moore SG, et al. · Expert Opin Pharmacother 2026
Also in development for Plaque Psoriasis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- EnvudeucitinibPhase 34 trials
Alumis Inc · Plaque Psoriasis, SLE
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- NetakimabPhase 32 trials
Biocad · Plaque Psoriasis
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- piclidenosonPhase 32 trials
Can-Fite BioPharma · Plaque Psoriasis, Lowe Syndrome
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.